Analyst Price Targets — NBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 16, 2026 3:40 pm | Andres Maldonado | H.C. Wainwright | $9.00 | $2.86 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback |
| October 27, 2025 10:53 am | Andrew Fein | H.C. Wainwright | $7.00 | $4.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on I-Mab (IMAB) |
| October 3, 2025 10:17 am | — | Leerink Partners | $9.00 | $4.13 | TheFly | I-Mab initiated with an Outperform at Leerink |
| September 10, 2025 5:29 pm | — | New Street | $7.00 | $4.18 | TheFly | BTIG says buy I-Mab amid 'misperceived' China risk |
| August 28, 2025 5:15 pm | Kumaraguru Raja | Loop Capital Markets | $8.00 | $4.25 | StreetInsider | I-Mab (IMAB) PT Raised to $8 at Brookline Capital Markets |
Latest News for NBP
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026.
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today…
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company's senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of NovaBridge's management team will participate in the upcoming H.C.
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmology Strengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NBP.
U.S. House Trading
No House trades found for NBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.